Prima applies for IND
Tuesday, 28 April, 2009
Sydney’s Prima BioMed has begun the application process for an investigational new drug with the US FDA for its CVac ovarian cancer adjuvant vaccine.
The Sydney company has also raised an extra $1.5 million from a significant new investor, on top of the $12 million funding facility it secured from investment back Fortrend Securities in March.
Prima is also offering a share purchase plan for existing shareholders to help fund its upcoming pivotal trial.
The company is treating one patient in Australia under the TGA’s special access scheme and has progressed through early stage trials.
CVac is a vaccine administered after surgery and chemotherapy to delay relapse and control metastases. It consists of a mannan fusion protein to target mucin 1 on cancer cells, which stimulates the immune system to attack the tumour.
Heart muscle regeneration genes mapped
Researchers have uncovered insights into how stem cells develop and mature into heart muscle...
The cause of 2022's mpox outbreak revealed
Researchers have discovered that the strain of mpox behind the 2022 outbreak was a weakened form...
New gene therapy treats liver disorder in growing children
Researchers have developed a genome-editing approach that repairs a faulty gene directly at its...
